Abstract
Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is discovered in 1994 from Kaposi’s sarcoma (KS) lesion of an acquired immunodeficiency syndrome (AIDS) patient. In addition to its association with KS, KSHV has also been implicated as the causative agent of two other AIDS-associated malignancies: primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). KSHV is a complex DNA virus that not only has the ability to promote cellular growth and survival for tumor development, but also can provoke deregulated angiogenesis, inflammation, and modulate the patient’s immune system in favor of tumor growth. As KSHV is a necessary but not sufficient etiological factor for KS, human immunodeficiency virus (HIV) is a very important cofactor. Here we review the basic information about the biology of KSHV, development of pathogenesis and interaction between KSHV and HIV.
Similar content being viewed by others
References
Ablashi D, Chatlynne L, Cooper H,et al. 1999. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer, 81: 893–897.
Ablashi D V, Chatlynne L G, Whitman J E Jr,et al. 2002. Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev, 15: 439–464.
Albini A, Paglieri I, Orengo G,et al. 1997. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi’s sarcoma-derived cells and a new immortalized Kaposi’s sarcoma cell line. AIDS, 11: 713–721.
Aoki Y, Tosato G. 2003. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect Disord, 3: 115–128.
Aoki Y, Tosato G. 2004. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood, 104: 810–814.
Atkinson J, Edlin B R, Engels E A,et al. 2003. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis, 187: 974–981.
Bechtel J T, Liang Y, Hvidding J,et al. 2003. Host range of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol, 77: 6474–6481.
Beral V. 1991. Epidemiology of Kaposi’s sarcoma. Cancer Surv, 10: 5–22.
Beral V, Peterman T A, Berkelman R L,et al. 1990. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet, 335: 123–128.
Blackbourn D J, Lennette E T, Ambroziak J,et al. 1998. Human herpesvirus 8 detection in nasal secretions and saliva. J Infect Dis, 177: 213–216.
Blackbourn D J, Osmond D, Levy J A,et al. 1999. Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. J Infect Dis, 179: 237–239.
Borkovic S P, Schwartz R A. 1981. Kaposi’s sarcoma presenting in the homosexual man — a new and striking phenomenon! Ariz Med, 38: 902–904.
Burysek L, Yeow W S, Lubyova B,et al. 1999. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol, 73: 7334–7342.
Cannon M J, Dollard S C, Black J B,et al. 2003. Risk factors for Kaposi’s sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS, 17: 215–222.
Carbone A, Gaidano G. 1997. HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. Br J Haematol, 97: 515–522.
Caselli E, Menegazzi P, Bracci A,et al. 2001. Human herpesvirus-8 (Kaposi’s sarcoma-associated herpesvirus) ORF50 interacts synergistically with the tat gene product in transactivating the human immunodeficiency virus type 1 LTR. J Gen Virol, 82: 1965–1970.
Caselli E, Galvan M, Santoni F,et al. 2003. Human herpesvirus-8 (Kaposi’s sarcoma-associated virus) ORF50 increases in vitro cell susceptibility to human immunodeficiency virus type 1 infection. J Gen Virol, 84: 1123–1131.
Caselli E, Galvan M, Cassai E,et al. 2003. Transient expression of human herpesvirus-8 (Kaposi’s sarcoma-associated herpesvirus) ORF50 enhances HIV-1 replication. Intervirology, 46: 141–149.
Caselli E, Galvan M, Cassai E,et al. 2005. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood, 106: 2790–2797.
Cathomas G, McGandy C E, Terracciano L M,et al. 1996. Detection of herpesvirus-like DNA by nested PCR on archival skin biopsy specimens of various forms of Kaposi sarcoma. J Clin Pathol, 49: 631–633.
Cesarman E, Chang Y, Moore P S,et al. 1995. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med, 332: 1186–1191.
Cesarman E. 2002. The role of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Recent Results Cancer Res, 159: 27–37.
Chang Y, Cesarman E, Pessin M S,et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science, 266: 1865–1869.
Chatlynne L G, Ablashi D V. 1999. Seroepidemiology of Kaposi’s sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol, 9: 175–185.
Chatlynne L G, Lapps W, Handy M,et al. 1998. Detection and titration of human herpesvirus-8-specific antibodies in sera from blood donors, acquired immuno-deficiency syndrome patients, and Kaposi’s sarcoma patients using a whole virus enzyme-linked immunosorbent assay. Blood, 92: 53–58.
Cheng E H, Nicholas J, Bellows D S,et al. 1997. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A, 94: 690–694.
Child E S, Mann D J. 2001. Novel properties of the cyclin encoded by Human Herpesvirus 8 that facilitate exit from quiescence. Oncogene, 20: 3311–3322.
Couty J P, Geras-Raaka E, Weksler B B,et al. 2001. Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells. J Biol Chem, 276: 33805–33811.
de-The G, Bestetti G, van Beveren M,et al. 1999. Prevalence of human herpesvirus 8 infection before the acquired immunodeficiency disease syndrome-related epidemic of Kaposi’s sarcoma in East Africa. J Natl Cancer Inst, 91: 1888–1889.
Dedicoat M, Newton R, Alkharsah K R,et al. 2004. Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis, 190: 1068–1075.
Duus K M, Lentchitsky V, Wagenaar T,et al. 2004. Wild-type Kaposi’s sarcoma-associated herpesvirus isolated from the oropharynx of immune-competent individuals has tropism for cultured oral epithelial cells. J Virol, 78: 4074–4084.
Enbom M, Sheldon J, Lennette E,et al. 2000. Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: variable frequencies found in a multicenter serological study. J Med Virol, 62: 498–504.
Engels E A, Sinclair M D, Biggar R J,et al. 2000. Latent class analysis of human herpesvirus 8 assay performance and infection prevalence in sub-saharan Africa and Malta. Int J Cancer, 88: 1003–1008.
Ensoli B, Sgadari C, Barillari G,et al. 2001. Biology of Kaposi’s sarcoma. Eur J Cancer, 37: 1251–1269.
Ensoli B, Sturzl M, Monini P. 2001. Reactivation and role of HHV-8 in Kaposi’s sarcoma initiation. Adv Cancer Res, 81: 161–200.
Field N, Low W, Daniels M,et al. 2003. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci, 116: 3721–3728.
Friborg J Jr, Kong W, Hottiger M O,et al. 1999. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature, 402: 889–894.
Friedman-Kien A E. 1981. Disseminated Kaposi’s sarcoma syndrome in young homosexual men. J Am Acad Dermatol, 5: 468–471.
Gambus G, Bourboulia D, Esteve A,et al. 2001. Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. AIDS, 15: 1167–1174.
Gao S J, Boshoff C, Jayachandra S,et al. 1997. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene, 15: 1979–1985.
Gao S J, Kingsley L, Li M,et al. 1996. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi’s sarcoma. Nat Med, 2: 925–928.
Gessain A, Mauclere P, van Beveren M,et al. 1999. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer, 81: 189–192.
Giraldo G, Beth E, Haguenau F. 1972. Herpes-type virus particles in tissue culture of Kaposi’s sarcoma from different geographic regions. J Natl Cancer Inst, 49: 1509–1526.
Goedert J J, Cote T R, Virgo P,et al. 1998. Spectrum of AIDS-associated malignant disorders. Lancet, 351: 1833–1839.
Gottlieb G J, Ragaz A, Vogel J V,et al. 1981. A preliminary communication on extensively disseminated Kaposi’s sarcoma in young homosexual men. Am J Dermatopathol, 3: 111–114.
Grossman Z, Iscovich J, Schwartz F,et al. 2002. Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus8. Mayo Clin Proc, 77: 905–909.
Guasparri I, Keller S A, Cesarman E. 2004. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med, 199: 993–1003.
Guo H G, Pati S, Sadowska M,et al. 2004. Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat. J Virol, 78: 9336–9342.
Gwack Y, Hwang S, Byun H,et al. 2001. Kaposi’s sarcoma-associated herpesvirus open reading frame 50 represses p53-induced transcriptional activity and apoptosis. J Virol, 75: 6245–6248.
Hengge U R, Ruzicka T, Tyring S K,et al. 2002. Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis, 2: 344–352.
Hideshima T, Chauhan D, Teoh G,et al. 2000. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi’s sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res, 6: 1180–1189.
Huang L M, Chao M F, Chen M Y,et al. 2001. Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem, 276: 13427–13432.
Hymes K B, Cheung T, Greene J B,et al. 1981. Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet, 2: 598–600.
Hyun T S, Subramanian C, Cotter M A 2nd,et al. 2001. Latency-associated nuclear antigen encoded by Kaposi’s sarcoma-associated herpesvirus interacts with Tat and activates the long terminal repeat of human immunodeficiency virus type 1 in human cells. J Virol, 75: 8761–8771.
Iscovich J, Boffetta P, Franceschi S,et al. 2000. Classic kaposi sarcoma: epidemiology and risk factors. Cancer, 88: 500–517.
Jacobson L P, Jenkins F J, Springer G,et al. 2000. Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi’s sarcoma. J Infect Dis, 181: 1940–1949.
Juhasz A, Remenyik E, Konya J,et al. 2001. Prevalence and age distribution of human herpesvirus-8 specific antibodies in Hungarian blood donors. J Med Virol, 64: 526–530.
Juhasz I, Albelda S M, Elder D E,et al. 1993. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol, 143: 528–537.
Kaaya S F, Leshabari M T, Mbwambo J K. 1998. Risk behaviors and vulnerability to HIV infection among Tanzanian youth. J Health Popul Dev Ctries, 1: 51–60.
Kaposi M. 1872. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph, 4: 265–273.
Kirchhoff S, Sebens T, Baumann S,et al. 2002. Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter. J Immunol, 168: 1226–1234.
Lang M E, Lottersberger C, Roth B,et al. 1997. Induction of apoptosis in Kaposi’s sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin. AIDS, 11: 1333–1340.
Lennette E T, Blackbourn D J, Levy J A. 1996. Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients. Lancet, 348: 858–861.
Li M, Lee H, Yoon D W,et al. 1997. Kaposi’s sarcoma-associated herpesvirus encodes a functional cyclin. J Virol, 71: 1984–1991.
Liu L, Eby M T, Rathore N,et al. 2002. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem, 277: 13745–13751.
Lubyova B, Pitha P M. 2000. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J Virol, 74: 8194–8201.
Martin J N, Ganem D E, Osmond D H,et al. 1998. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med, 338: 948–954.
Martin R W 3rd, Hood A F, Farmer E R. 1993. Kaposi sarcoma. Medicine (Baltimore), 72: 245–261.
Matta H, Chaudhary P M. 2004. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci U S A, 101: 9399–9404.
Mayama S, Cuevas L E, Sheldon J,et al. 1998. Prevalence and transmission of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer, 77: 817–820.
Mbulaiteye S M, Biggar R J, Goedert J J,et al. 2003. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr, 32: 527–533.
Mbulaiteye S M, Pfeiffer R M, Whitby D,et al. 2003. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis, 187: 1780–1785.
Mendez J C, Procop G W, Espy M J,et al. 1999. Relationship of HHV8 replication and Kaposi’s sarcoma after solid organ transplantation. Transplantation, 67: 1200–1201.
Merat R, Amara A, Lebbe C,et al. 2002. HIV-1 infection of primary effusion lymphoma cell line triggers Kaposi’s sarcoma-associated herpesvirus (KSHV) reactivation. Int J Cancer, 97: 791–795.
Mercader M, Taddeo B, Panella J R,et al. 2000. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol, 156: 1961–1971.
Mercader M, Nickoloff B J, Foreman K E. 2001. Induction of human immunodeficiency virus 1 replication by human herpesvirus 8. Arch Pathol Lab Med, 125: 785–789.
Molden J, Chang Y, You Y,et al. 1997. A Kaposi’s sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem, 272: 19625–19631.
Montaner S, Sodhi A, Pece S,et al. 2001. The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res, 61: 2641–2648.
Moore P S, Chang Y. 2001. Molecular virology of Kaposi’s sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci, 356: 499–516.
Moore P S, Kingsley L A, Holmberg S D,et al. 1996. Kaposi’s sarcoma-associated herpesvirus infection prior to onset of Kaposi’s sarcoma. AIDS, 10: 175–180.
Moore P S, Gao S J, Dominguez G,et al. 1996. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcomae. J Virol, 70: 549–558.
Munshi N, Ganju R K, Avraham S,et al. 1999. Kaposi’s sarcoma-associated herpesvirus-encoded G protein-coupled receptor activation of c-jun amino-terminal kinase/stress-activated protein kinase and lyn kinase is mediated by related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2. J Biol Chem, 274: 31863–31867.
Nador R G, Cesarman E, Chadburn A,et al. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood, 88: 645–656.
Nakamura H, Li M, Zarycki J,et al. 2001. Inhibition of p53 tumor suppressor by viral interferon regulatory factor. J Virol, 75: 7572–7582.
Neipel F, Albrecht J C, Fleckenstein B. 1997. Cell-homologous genes in the Kaposi’s sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol, 71: 4187–4192.
O’Brien T R, Kedes D, Ganem D,et al. 1999. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposi’s sarcoma. J Infect Dis, 180: 1010–1017.
Oettle A G. 1962. Geographical and racial differences in the frequency of Kaposi’s sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum, 18: 330–363.
Olsen S J, Chang Y, Moore P S,et al. 1998. Increasing Kaposi’s sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi’s sarcoma endemic region, Zambia in 1985. AIDS, 12: 1921–1925.
Osborne J, Moore P S, Chang Y. 1999. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol, 60: 921–927.
Pati S, Cavrois M, Guo H G,et al. 2001. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi’s sarcoma pathogenesis. J Virol, 75: 8660–8673.
Pauk J, Huang M L, Brodie S J,et al. 2000. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med, 343: 1369–1377.
Plancoulaine S, Abel L, van Beveren M,et al. 2000. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet, 356: 1062–1065.
Plancoulaine S, Abel L, Tregouet D,et al. 2004. Respective roles of serological status and blood specific antihuman herpesvirus 8 antibody levels in human herpesvirus 8 intrafamilial transmission in a highly endemic area. Cancer Res, 64: 8782–8787.
Preiser W, Szep N I, Lang D,et al. 2001. Kaposi’s sarcoma-associated herpesvirus seroprevalence in selected german patients: evaluation by different test systems. Med Microbiol Immunol, 190: 121–127.
Rabkin C S, Janz S, Lash A,et al. 1997. Monoclonal origin of multicentric Kaposi’s sarcoma lesions. N Engl J Med, 336: 988–993.
Radkov S A, Kellam P, Boshoff C. 2000. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med, 6: 1121–1127.
Regamey N, Cathomas G, Schwager M,et al. 1998. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol, 36: 1784–1786.
Renne R, Blackbourn D, Whitby D,et al. 1998. Limited transmission of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol, 72: 5182–5188.
Renne R, Lagunoff M, Zhong W,et al. 1996. The size and conformation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol, 70: 8151–8154.
Rivas C, Thlick A E, Parravicini C,et al. 2001. Kaposi’s sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol, 75: 429–438.
Russo J J, Bohenzky R A, Chien M C,et al. 1996. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A, 93: 14862–14867.
Samaniego F, Young D, Grimes C,et al. 2002. Vascular endothelial growth factor and Kaposi’s sarcoma cells in human skin grafts. Cell Growth Differ, 13: 387–395.
Sarek G, Jarviluoma A, Ojala P M. 2006. KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood, 107: 725–732.
Sarid R, Flore O, Bohenzky R A,et al. 1998. Transcription mapping of the Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol, 72: 1005–1012.
Sarid R, Sato T, Bohenzky R A,et al. 1997. Kaposi’s sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med, 3: 293–298.
Schulz T F. 2000. KSHV (HHV8) infection. J Infect, 41: 125–129.
Schwarz M, Murphy P M. 2001. Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor cons-titutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J Immunol, 167: 505–513.
Seo T, Lee D, Shim Y S,et al. 2002. Viral interferon regulatory factor 1 of Kaposi’s sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. J Virol, 76: 8797–8807.
Seo T, Park J, Lee D,et al. 2001. Viral interferon regulatory factor 1 of Kaposi’s sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol, 75: 6193–6198.
Shin Y C, Nakamura H, Liang X,et al. 2006. Inhibition of the ATM/p53 signal transduction pathway by Kaposi’s sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol, 80: 2257–2266.
Siegal F P, Lopez C, Hammer G S,et al. 1981. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med, 305: 1439–1444.
Sitas F, Carrara H, Beral V,et al. 1999. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med, 340: 1863–1871.
Smit M J, Verzijl D, Casarosa P,et al. 2002. Kaposi’s sarcoma-associated herpesvirus-encoded G protein-coupled receptor ORF74 constitutively activates p44/p42 MAPK and Akt via G(i) and phospholipase C-dependent signaling pathways. J Virol, 76: 1744–1752.
Soulier J, Grollet L, Oksenhendler E,et al. 1995. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood, 86: 1276–1280.
Sternbach G, Varon J. 1995. Moritz Kaposi: idiopathic pigmented sarcoma of the skin. J Emerg Med, 13: 671–674.
Sturzl M, Hohenadl C, Zietz C,et al. 1999. Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi’s sarcoma spindle cells. J Natl Cancer Inst, 91: 1725–1733.
Sun Q, Matta H, Chaudhary P M. 2005. Kaposi’s sarcoma associated herpes virus-encoded viral FLICE inhibitory protein activates transcription from HIV-1 Long Terminal Repeat via the classical NF-kappaB pathway and functionally cooperates with Tat. Retrovirology, 2: 9.
Wan X, Wang H, Nicholas J. 1999. Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. J Virol, 73: 8268–8278.
West J T, Wood C. 2003. The role of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene, 22: 5150–5163.
Whitby D, Howard M R, Tenant-Flowers M,et al. 1995. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet, 346: 799–802.
Whitby D, Luppi M, Barozzi P,et al. 1998. Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst, 90: 395–397.
Zeng Y, Zhang X, Huang Z,et al. 2007. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi’s sarcoma-associated herpesvirus: role of JAK/STAT signaling. J Virol, 81: 2401–2417.
Zhu F X, Chong J M, Wu L,et al. 2005. Virion proteins of Kaposi’s sarcoma-associated herpesvirus. J Virol, 79: 800–811.
Ziegler J L, Newton R, Katongole-Mbidde E,et al. 1997. Risk factors for Kaposi’s sarcoma in HIV-positive subjects in Uganda. AIDS, 11: 1619–1626. VIROLOGICA SINICA, December 2008, 23 (6):486–495
Author information
Authors and Affiliations
Corresponding author
Additional information
Foundation items: Fok Ying Tung Education Foundation (101038) and Program for New Century Excellent Talents in Chinese Universities (NCET-05-0506).
Rights and permissions
About this article
Cite this article
Qin, D., Lu, C. The biology of Kaposi’s sarcoma-associated herpesvirus and the infection of human immunodeficiency virus. Virol. Sin. 23, 473–485 (2008). https://doi.org/10.1007/s12250-008-2996-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-008-2996-x